DM Options

Full-Time Options Trader. Started trading in 1997. +92% YTD in 2024. Low $ xx,xxx,xxx 👑

[DM Options @DMOptions]

Roughly 500 trades. Mostly trading around catalysts using options.

Most of my trades done on my iPhone. I usually wake up after the market has opened. When I do trade from my computer, I use a single monitor. I don't have a Bloomberg terminal. Lots of ways to make money in this game. Risk management over everything. Started in this game in 1997 as a teenager and still going strong.

Thanks to everyone who posted research on X this year. This is the best job in the world. Don't give up.

[DM Options @DMOptions]

The same institution that did the big up-and-out roll on $QURE earlier this week (to the October $65 calls) likely added another 500 calls yesterday. They broke it up into smaller trades around lunchtime.

There are now almost 3,000 of these contracts (October $65 calls) in OI, up from 909 at the end of June

[DM Options @DMOptions]

@peter_mantas Drinks on me in Vegas if this happens - everyone is invited

[DM Options @DMOptions]

Me if I'd been offered an allocation of the $ABVX secondary

[DM Options @DMOptions]

$ABVX Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database

[DM Options @DMOptions]

$QURE upsized $225 million offering @ $45.50

[DM Options @DMOptions]

Me too.

I had something like 67,000 shares over two accounts going into last week's news, plus a bunch of options positions that I picked up along the way.

I got out of all of this after last week's positive news, and I started accumulating call and ratio spreads targeting the $80 and $90 price levels.

$QURE

[DM Options @DMOptions]

Casual $2 million bet on $QURE Jan '28 $40/$100 bull call spread

[DM Options @DMOptions]

@Lucy3370 Most of the big orders over the last week have been sweeps, and those are usually institutions who want in quickly (filled at the ask, broken up over multiple exchanges) $QURE

[Dirk Haussecker @RNAiAnalyst]

$qure with the market being fixated on Huntington's, I view AMT-260 as pure upside. Cohort 1 (n=6) data to be presented this Friday.

[DM Options @DMOptions]

Jan $70 sweeper back for more today $QURE

[DM Options @DMOptions]

Somebody is absolutely hammering these January $70 calls in $QURE today

[DM Options @DMOptions]

+3,495 of these contracts were added to open interest yesterday btw $QURE

[mike @mike98572986]

$qure $clpt

Uhhh guys, FDA just gave the playbook, they just told us directly what they think about natural history for HD here.. This is the FDA speaking here. This was June 5, 2026, Lauren Holder also spoke. 2 hd people spoke. Why do you think the FDA specifically requested Lauren to be there and speak?? -) Not sure what else the new FDA can say, they basically just specifically called out HD and natural history..

Look who was one of the main hosts and also spoke

Teresa Buracchio- the same Teresa that said

“FDA official confirms plausible mechanism principles not exclusive to bespoke gene therapies”

Michelle Campbell FDA 35.48 to 36.38 woah….
Look what she says about HD..

FDA again 1:36 - 1:39- big time big time, FDA calls out HD and natural history.

“Natural history is going to be paramount and fundamental to how we really think about the understanding of the disease!”

“Whether it’s ALS, Huntington’s, or a neurodegenerative disease, The truth is the same, time matters.” @laurencurehd spoke from 1:28

https://t.co/hhBQTI38Ag

https://t.co/3a79ub7q2F

@peter_mantas @Tim_Corr @DesertDweller93 @Prof_Dollar @biggercapital @Christina4HD

[Christina D @Christina4HD]

Yesterday, we spoke to the @FDA about why Huntington’s disease should be considered a national priority under the CNPV Pilot Program.

Now the FDA is asking for public comments, and our community has an opportunity to be heard.

Please take a few minutes to submit a comment asking the FDA to prioritize fatal, progressive neurodegenerative diseases like Huntington’s when promising therapies are ready for review.

Comment here:
https://t.co/24u6kb42wV

Comments close June 29 at 11:59 PM ET.

#HuntingtonsDisease #HDCommunity #RareDisease

[Christina D @Christina4HD]

Tomorrow at 1:00 PM ET, join @KarlMiran & me as we discuss why Huntington’s disease should be a priority for the FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program.

When promising therapies are ready, families facing fatal neurodegenerative diseases deserve a regulatory pathway that reflects the urgency of what is being lost every day.

Watch live: https://t.co/L73f2lU3wB

#HuntingtonsDisease
#RareDisease

[DM Options @DMOptions]

FDA meeting went well today - I'm assuming this is why $QURE is up in AH

Jeff Allen told Reuters that meeting was a "breath of fresh air"

[John Mason @johnkmason]

Adding more $QURE here. I added 3% back this week at $25 as it bottomed out and now another 3%.

I cannot believe how little readthrough $REPL reversal is flowing to $QURE. $REPL had more questionable data (search X for good pts), esp relative to HD's magnitude of unmet need.

[DM Options @DMOptions]

Interactive Brokers better send me a gift basket or something for Christmas this year

[DM Options @DMOptions]

Karim Mikhael as the acting CBER head is a home run - read his comments from the JP Morgan Health Conference in January $QURE

[Rachel Cohrs Zhang @rachelcohrs]

New: FDA's top drug regulator Tracy Beth Høeg is departing the agency following Marty Makary's exit earlier this week. CDER deputy director Mike Davis will serve as acting director https://t.co/RdzTez6K0p